<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05048160</url>
  </required_header>
  <id_info>
    <org_study_id>6MW3211-2021-CP101</org_study_id>
    <nct_id>NCT05048160</nct_id>
  </id_info>
  <brief_title>A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm</brief_title>
  <official_title>Phase I/II Clinical Trial of 6MW3211 Injection to Evaluate Safety, Tolerability, PK/PD, Immunogenicity and Preliminary Efficacy in Subjects With Advanced Malignant Neoplasm.(Only Phase I Has Been Submitted to US FDA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mabwell (Shanghai) Bioscience Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mabwell (Shanghai) Bioscience Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single arm, non-randomized, open label, multiple doses phase I/II&#xD;
      international, multicenter clinical trial to evaluate safety, tolerability, PK/PD,&#xD;
      immunogenicity and preliminary efficacy in subjects with advanced malignant neoplasm. The&#xD;
      study is consisted of two stages: dose escalation and clinical expansion.&#xD;
&#xD;
      Only Phase I has been submitted to US FDA,and the protocol number is still the same as&#xD;
      6MW3211-2021-CP101.The US title is : A Phase 1, First-in-Human (FIH), Multicenter,&#xD;
      Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and&#xD;
      Pharmacodynamics of 6MW3211 in Patients with Advanced Malignancies .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Six cohorts are included in dose escalation stage, at doses of 0.3~45 mg/kg, respectively.&#xD;
      Safety, tolerability, and dose-limiting toxicity (DLT) are assessed during the first 3 weeks&#xD;
      (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks&#xD;
      (Q2W), IV.&#xD;
&#xD;
      From the first study drug administration, some dosing cycles will be observed for phase I,&#xD;
      initial tumor efficacy assessments will be performed at week 7, after that tumor efficacy&#xD;
      assessment will be carry out for every 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs</measure>
    <time_frame>Up to 28 days post last dose</time_frame>
    <description>All the adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>1 Year</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DOR</measure>
    <time_frame>1 Year</time_frame>
    <description>Duration of Remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>1 Year</time_frame>
    <description>Progression-Free Survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DCR</measure>
    <time_frame>1 Year</time_frame>
    <description>Disease Control Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>1 Year</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK Parameters</measure>
    <time_frame>1 Year</time_frame>
    <description>The area under the curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters</measure>
    <time_frame>1 Year</time_frame>
    <description>Maximum concentration(Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters</measure>
    <time_frame>1 Year</time_frame>
    <description>Time at which maximum concentration(Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameters</measure>
    <time_frame>1 Year</time_frame>
    <description>The half life(T1/2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">272</enrollment>
  <condition>Advanced Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>6MW3211</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosage form: injection&#xD;
Specification: 240 mg / 8 ml/Vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Infusion</intervention_name>
    <description>Dose-limiting toxicity (DLT) are assessed during the first 3 weeks (21 days) after initial administration. Then, the intended dosing frequency is every 2 weeks (Q2W).</description>
    <arm_group_label>6MW3211</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Men or women, age â‰¥18.&#xD;
&#xD;
          -  2.Subjects with advanced malignancy histopathologically and/or cytologically, with at&#xD;
             least one evaluable tumor lesion.&#xD;
&#xD;
          -  3.ECOG PS is 0 or 1.&#xD;
&#xD;
          -  4.Survival expectation of at least 3 months.&#xD;
&#xD;
          -  5.Adequate organs and hematopoietic functions&#xD;
&#xD;
          -  6.Voluntarily signing of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Subjects with brain metastases of clinically active central nervous system (CNS).&#xD;
&#xD;
          -  2.Subjects that require to take anticoagulants and/or aspirin.&#xD;
&#xD;
          -  3.Blood transfusion within 2 weeks prior to the first administration of study&#xD;
             treatment.&#xD;
&#xD;
          -  4.Inadequately controlled body cavity effusions.&#xD;
&#xD;
          -  5.Subjects with active, or have a history and possible recurrence of autoimmune&#xD;
             diseases .&#xD;
&#xD;
          -  6.Have uncontrolled systemic diseases.&#xD;
&#xD;
          -  7.Subjects who had received anticancer therapy or radiotherapy within 4 weeks or 5&#xD;
             half-lives (whichever is shorter) before enrollment.&#xD;
&#xD;
          -  8.Subjects are known to have previously experienced severe allergic reactions to large&#xD;
             molecular protein formulations/monoclonal antibodies.&#xD;
&#xD;
          -  9.Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University Cancer Hospital of China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Zhang, Professor</last_name>
    <phone>18017312991</phone>
    <email>syner2000@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Zhang, Professor</last_name>
      <phone>18017312991</phone>
      <email>syner2000@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 31, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

